Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics (NYSE American: OGEN) signed a non-binding Letter of Intent to license Sigyn Therapeutics' CardioDialysis™ blood‑purification technology for TBI and other neurodegenerative indications. The LOI contemplates 3,250,000 convertible restricted preferred shares to Sigyn, a 3% royalty for six years post-clearance, and a target close within 90 days subject to due diligence and approvals.
Strategic rationale: combining ONP-002 intranasal neurosteroid (crosses the blood‑brain barrier) with CardioDialysis™ (systemic inflammation clearance) to address TBI inflammation both centrally and peripherally.
Oragenics (NYSE American: OGEN) activated a second site, Alfred Hospital, in its Phase IIa study of ONP-002 for concussion and mild traumatic brain injury. Four patients have been dosed at Mackay Base Hospital; the trial plans to enroll 40 patients with first dosing within 12 hours.
Phase IIa data are projected before year-end 2026 and the company targets an IND submission for a Phase IIb U.S. trial by Dec 31, 2026.
Oragenics (NYSE American: OGEN) announced that 2 patients have been dosed and 8 study drug doses administered in its ongoing Phase IIa trial of ONP-002 for mild traumatic brain injury (mTBI) as of April 20, 2026.
The trial is designed to enroll 40 patients, with first dosing within 12 hours of concussion and treatment up to 30 days; Mackay Base Hospital is the first activated site and additional sites are finalizing activation.
Oragenics (NYSE: OGEN) announced dosing of the first patient in its Phase IIa trial of ONP-002 for concussion/mild traumatic brain injury at Mackay Hospital, Australia, within days of site activation on March 31, 2026. The randomized, placebo-controlled 40-patient study will dose within 12 hours of injury and continue treatment up to 30 days.
The company cited a Phase I safety profile with zero serious adverse events in 40 patients, HREC clearance in Australia, CRO support from Southern Star Research, and planned IND targeting in Q4 2026.
Oragenics (NYSE American: OGEN) announced receipt of an unqualified audit opinion on its consolidated financial statements, which included an explanatory paragraph about the Company’s ability to continue as a going concern. The Form 10-K for the year ended December 31, 2025 was filed March 16, 2026.
The announcement complies with NYSE American Company Guide Section 610(b) and does not amend or change the audited financial statements; supporting detail appears in footnote 1 of the 2025 consolidated financial statements. The 10-K is available on the SEC EDGAR system and the company’s investor relations website.
Oragenics (NYSE American: OGEN) filed its Form 10-K for the fiscal year ended December 31, 2025 and provided a shareholder update on 2025 milestones and Q1 2026 progress.
Key 2025 highlights include a $16.5 million capital raise, repayment of a $3.0 million promissory note, an 11% reduction in operating expenses, US cGMP manufacturing engagement, CRO contracting for a Phase IIa trial, and a partnership with Receptor.AI. Q1 2026 updates include HREC approval in Australia, initial site initiation visit, and IND readiness work with DUCK FLATS Pharma.
Oragenics (NYSE American: OGEN) completed the first site initiation visit for its Phase IIa trial of ONP-002 in Australia on March 12, 2026.
First SIV finished at one of three planned Australian sites; two remaining sites are completing Research Governance Office reviews after Human Research Ethics Committee approval. The randomized, placebo-controlled trial targets 40 patients, dosing within 12 hours of concussion onset, with primary endpoints around safety, neurocognitive assessments, and tolerability.
Oragenics (NYSE American: OGEN) is exploring acquisition of CNS assets focused on brain health and brain recovery to complement its intranasal delivery platform and lead candidate ONP-002.
ONP-002 Phase IIa is in active site initiation in Australia; Phase 1 showed safety in 40 patients with zero serious adverse events. No definitive acquisition agreements have been reached; any material transaction will be disclosed as required.
Oragenics (NYSE: OGEN) received final Human Research Ethics Committee (HREC) approval in Australia to begin a randomized, placebo-controlled Phase IIa trial of ONP-002 for concussion/mild traumatic brain injury. The trial will enroll 40 patients across three Australian sites, with first dosing expected before the end of March 2026 and a data readout projected before year-end 2026. Patients will receive first dosing within 12 hours of injury and up to 30 days of treatment; the company cites a Phase 1 safety profile with zero serious adverse events. Trial management is expected to be handled by Southern Star Research.
Oragenics (NYSE American: OGEN) previewed 2026 milestones for ONP-002, a first-in-class intranasal neurosteroid targeting concussion and mild traumatic brain injury (mTBI). The company says it has a fully funded Phase 2a trial (40 patients) with U.S. cGMP manufacturing, a CRO selection, a strategic AI collaboration, and $16.5 million raised.
Near-term goals include Australian site onboarding, first patient dosing, interim data during 2026, a Q4 2026 final readout, and an FDA IND submission for U.S. trials.